Zobrazeno 1 - 10
of 90
pro vyhledávání: '"Pippa S. Loupe"'
Autor:
Frank Schneider, Margaret Bradbury, Thomas A. Baillie, David Stamler, Edward Hellriegel, Donna S. Cox, Pippa S. Loupe, Juha‐Matti Savola, Laura Rabinovich‐Guilatt
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 4, Pp 707-717 (2020)
Deutetrabenazine (Austedo, Teva Pharmaceuticals) is a deuterated form of tetrabenazine. It is the first deuterated drug to receive US regulatory approval and is approved for treatment of chorea in Huntington’s disease and tardive dyskinesia. Two or
Externí odkaz:
https://doaj.org/article/488fd588e08e462d8e40b79611ffd5c1
Autor:
Frank Schneider, Borje Darpo, Pippa S. Loupe, Hongqi Xue, Helena Knebel, Maria Gutierrez, Mark Forrest Gordon, Laura Rabinovich‐Guilatt
Publikováno v:
Clinical pharmacology in drug developmentReferences. 12(1)
Deutetrabenazine (Austedo) is indicated in adults for chorea associated with Huntington disease and tardive dyskinesia. Escalating deutetrabenazine doses were administered to healthy volunteers who were cytochrome P450 2D6 extensive/intermediate meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5f588eb2485a61605abeb0cfd558235
https://pubmed.ncbi.nlm.nih.gov/36098670
https://pubmed.ncbi.nlm.nih.gov/36098670
Autor:
Edward T. Hellriegel, Mark Forrest Gordon, David Stamler, Margaret Bradbury, Pippa S. Loupe, Donna S. Cox, Laura Rabinovich-Guilatt, Frank Schneider, Juha-Matti Savola
Publikováno v:
Clinical Pharmacology in Drug Development
Deutetrabenazine (Austedo, Teva), an approved treatment of chorea in Huntington's disease and tardive dyskinesia in adult patients, is a rationally designed deuterated form of tetrabenazine. Two studies assessed the pharmacokinetics and safety of deu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e54d6898ca61ef367ef6156dbacbd254
https://doi.org/10.1002/cpdd.882
https://doi.org/10.1002/cpdd.882
Autor:
Pippa S. Loupe, David J. Greenblatt, Arik A. Zur, Anna Elgart, Dorit Mimrod, Sivan Weiss, Ofer Spiegelstein
Publikováno v:
Clinical Pharmacology in Drug Development. 9:1015-1024
Laquinimod, a neuroimmunomodulator, is extensively metabolized by cytochrome P450 (CYP) 3A4, and modulations of CYP3A4 activity may lead to alterations in the pharmacokinetics and/or clinical effects of laquinimod. To determine the drug-drug interact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac479ac6f68e5f541ad3be627cec9843
https://doi.org/10.1002/cpdd.785
https://doi.org/10.1002/cpdd.785
Autor:
Igor D. Grachev, Pippa S. Loupe, Spyros Papapetropoulos, Leehee Navon-Perry, Juha-Matti Savola, Shai Fine, Michael R. Hayden, Itzik Mazeh, Ralf Reilmann, Nicholas Gross, Mark Forrest Gordon, Yonatan Dolan
Publikováno v:
Digital Biomarkers. 3:103-115
Previous studies have demonstrated the feasibility and promise of wearable sensors as objective measures of motor impairment in Parkinson disease and essential tremor. However, there are few published studies that have examined such an application in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::884f747973900d0eec58a3c56ebfd622
https://doi.org/10.1159/000502136
https://doi.org/10.1159/000502136
Autor:
Andrijana Radivojevic, Pippa S. Loupe, Michael Brennan, Xiaoping Ning, Michael Gillespie, Orit Cohen-Barak, Andrew H. Ahn, Yoel Kessler, Aksana Jones, Michele Rasamoelisolo, Laura Rabinovich-Guilatt, Jill Fiedler-Kelly, Dikla Gutman, Micha Levi, Hussein Hallak
Publikováno v:
Cephalalgia : an international journal of headache. 41(10)
Background Potential fremanezumab doses for pediatric patients were evaluated using pharmacokinetic modeling and simulation. An open-label phase 1 pharmacokinetic and safety study was conducted in pediatric patients with migraine. This study’s resu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52808ded1741d75d6d3addb117322f06
https://pubmed.ncbi.nlm.nih.gov/34000848
https://pubmed.ncbi.nlm.nih.gov/34000848
Autor:
Shawn Li, Honglue Shen, Irina Cherniakov, Ryan Tiver, Hussein Hallak, Michael Smith, Ofer Spiegelstein, Pippa S. Loupe, Yoel Kessler, Laura Rabinovich-Guilatt, Michael Gillespie, Maria Gutierrez, Orit Cohen-Barak, Michele Rasamoelisolo
Publikováno v:
Clinical Pharmacology in Drug Development
Fremanezumab (AJOVY; Teva Pharmaceutical Industries Ltd, Netanya, Israel), approved for the preventive treatment of migraine, is available as a subcutaneous injection either once a month or once every 3 months using an autoinjector or a prefilled syr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5b185b3a69b852e709c6261a04bed58
https://pubmed.ncbi.nlm.nih.gov/33411992
https://pubmed.ncbi.nlm.nih.gov/33411992
Autor:
Juliana H. VanderPluym, David W. Dodick, Pippa S. Loupe, Yuju Ma, Richard B. Lipton, Marcelo E. Bigal
Publikováno v:
Neurology. 91:e1152-e1165
ObjectiveTo evaluate the effect of fremanezumab on the functional status on headache-free days in phase 2 episodic migraine (EM) and chronic migraine (CM) studies.MethodsFunctional status data were collected prospectively via the electronic headache
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb90a44f170899e4e5667df6647a148a
https://doi.org/10.1212/01.wnl.0000544321.19316.40
https://doi.org/10.1212/01.wnl.0000544321.19316.40
Autor:
Hooman Beygi, Igor D. Grachev, Juha-Matti Savola, Micha Levi, Serge Guzy, Margaret Bradbury, Pippa S. Loupe, Lavi Erisson, Ofer Spiegelstein, Maria Velinova, Spyros Papapetropoulos, William Tracewell, Mirna McDonald, Orit Cohen-Barak, Frank Schneider
Publikováno v:
British Journal of Clinical Pharmacology. 84:2422-2432
AIMS SD-1077, a selectively deuterated precursor of dopamine (DA) structurally related to L-3,4-dihydroxyphenylalanine (L-DOPA), is under development for treatment of motor symptoms of Parkinson's disease. Preclinical models have shown slower metabol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66afb0fc32dce1d2a72c8a6e5722f9e3
https://doi.org/10.1111/bcp.13702
https://doi.org/10.1111/bcp.13702
Autor:
Ernesto Aycardi, Marcelo E. Bigal, Rashmi B. Halker Singh, David W. Dodick, Pippa S. Loupe, Mirna McDonald
Publikováno v:
Cephalalgia. 39:52-60
Background In phase 2 and 3 studies, fremanezumab, a monoclonal CGRP antibody, was an effective preventive treatment for high-frequency episodic migraine (HFEM) and chronic migraine (CM). Objective Post-hoc analyses evaluated population-wise 50%, 75%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70608901866d9007d7bebda0b9d63720
https://doi.org/10.1177/0333102418772585
https://doi.org/10.1177/0333102418772585